High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...

AbbVie will pay Danish antibody specialist Genmab ... for Tepezza (teprotumumab), an antibody for the treatment of thyroid eye disease. Its biggest success to date by a long margin is the alliance ...

Instead, it allowed for a blood sample to be inoculated with a radioactive form of thyroid hormone ... The creation of AbbVie In 2011, Abbott announced it was to separate into two leading ...

It's encouraging to see that AbbVie has been growing its earnings per share at 5.7% a year over the past five years. While EPS is growing at a decent rate, but future growth could be limited by ...

Day two of the J.P Morgan Healthcare Conference rolled on with positive data from Sling Therapeutics Inc. that is leading the company to a phase III study in treating thyroid eye disease. The ...

In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer ...

AbbVie, with a market cap of over $300 billion, shows strong cash flow potential despite patent expirations, making it a valuable investment. The company reported strong 3Q financials, with ...

AbbVie will write off $3.5 billion related to its $8.7 billion investment in Cerevel Therapeutics following the failure of the company's key schizophrenia drug, emraclidine, The Wall Street ...

The aim of this study was to investigate the effect of levothyroxine replacement therapy on biomarkers of oxidative stress (OS) and systemic inflammation in patients with hypothyroidism.

AbbVie will take an impairment charge of approximately $3.5 billion related to the back-to-back failures of its pricey drug candidate emraclidine in two mid-stage schizophrenia trials, the pharma ...